Although placental lactogens exhibit biological activities similar to those of growth hormone (somatotropin) and prolactin, the primate hormone often demonstrates activities that are difficult to explain by an interaction with the growth hormone or prolactin receptor alone (1). Both growth hormone and human placental lactogen stimulate the release of free fatty acids from epididymal fat pads, but this action of hPL is not potentiated by dexamethasone, a characteristic of lipolysis induced by growth hormone (2); furthermore, hPL has a greater effect on glycerol release than does growth hormone (3) . Growth hormone stimulates a-aminoisobutyric acid transport and weight gain in immature mouse uteri, while hPL significantly decreases both (4) . In addition, preliminary data from this laboratory have suggested that the target organ specificity of placental lactogen may be different from that of growth hormone or prolactin, since growth hormone and prolactin stimulate ornithine decarboxylase activity in both brain and liver, but hPL stimulates only the brain enzyme (5) .
Subprimate placental lactogens also exhibit biological activities not shared by other hormones of the growth hormoneprolactin family. When injected into starved sheep, ovine placental lactogen (oPL) produces a marked and prolonged depression in free fatty acids (6) , in contrast to the elevation seen with growth hormone (7); and oPL stimulates insulin release (6) , while growth hormone does not (8) . These data have suggested that placental lactogens may act, at least in some tissues, through receptors distinct from those for growth hormone or prolactin. Although it has been observed that hPL and prolactin bind to identical receptors in rabbit mammary tissue (9) tablished the hormonal specificity of binding by displacement of hPL with growth hormone or prolactin. This investigation was undertaken as a search for specific placental lactogen binding that might explain the unique aspects of placental lactogen actions described above.
MATERLALS AND METHODS
Bovine growth hormone (NIH-BGH-B17), bovine prolactin (NIH-P-B3), and human placental lactogen were kindly provided by the Hormone Distribution Program, NIAMDD. The first two hormones were further purified on a column of Sephadex G-150 as described (12) . The preparation of bovine and ovine placental lactogens has been reported elsewhere, (13, 14) .
All hormones were greater than 95% pure, as determined by end-group analysis. The oPL was iodinated by the lactoperoxidase method of Miyachi et al. (15) , as modified by Bolander and Fellows (16) , and had a specific activity of 44 ,Ci/gg.
Tissues were obtained from New Zealand albino rabbits on the 29th or 30th day of gestation. Membrane fractions were prepared by homogenization in a Tekmar Tissumizer (Model SDT), followed by a series of differential centrifugations as described by Shiu et al. (9) . Tissues were processed within one week of sacrifice, since it has been reported that significant degradation of receptors occurs in material stored longer than one week at -20° (17) . After processing, the receptor activity has been found to be stable at -200 for at least 1 year (Bolander and Fellows, unpublished observations).
Binding studies were conducted with 1.5 mg of tissue per assay tube, with protein concentration determined by the method of Lowry et al. (18) . The tracer and hormones were dissolved in 25 mM Tris.HCI, pH 7.6, containing 10 mM MgCl2 and 0.1% bovine serum albumin. Each assay tube contained 50,000-100,000 cpm of 125I-labeled oPL, a known amount of hormone, and buffer to a total volume of 0.5 ml. The samples were incubated at room temperature for 5 hr with Vortex mixing at 30-min intervals. At the end of the incubation period, 3 ml of ice-cold buffer were added to each tube. The samples were centrifuged at 12,000 X g for 30 Since these data (Table 1) represent the displacing activity at a single concentration, they do not provide an accurate comparison of relative potencies of these hormones. In order to obtain additional information about potency and binding characteristics, we established displacement curves for each hormone with rabbit mammary gland (Fig. 1) and liver membrane fractions (Fig. 2) . In each tissue, the displacement curves for oPL, hPL, and bPR are identical and the concentrations of each hormone required to inhibit tracer binding by 50% do not significantly differ from each other ( Table 2 ). The displacement curves for bGH and bPL are parallel to those of oPL and bPR but shifted to the right, suggesting that bGH and bPL bind at the lactogenic site with significantly lower affinity.
Further analysis of 125I-labeled oPL binding by Scatchard plots (Fig. 3) reveals Ka values of 3.63 X 109 and 3.41 X 109 Mfor mammary and liver tissue, respectively. The binding ca- 
DISCUSSION
Tissues from late pregnant rabbits were used in this study, because they have the highest binding for prolactin and growth hormone of any well-studied species (20) . Furthermore, these animals also produce a placental lactogen, which is currently being characterized in this laboratory (Bolander and Fellows, unpublished observations), and thus provide a logical experimental model for the study of interactions between placental lactogen and receptor. The use of subprimate hormones in this investigation offers a significant advantage for the study of receptor specificity, because of the absence of cross-binding between growth hormone and prolactin for their receptors. In contrast, primate growth hormone has intrinsic lactogenic activity, being equipotent to prolactin in the local intraductal assay in pseudopregnant rabbits (19) , and also binds to the same receptors as prolactin in the rat and the rabbit (17) .
Specific binding of '25I-labeled oPL is highest in the adrenal gland (57.8%), and is comparable to the binding of prolactin in this organ (51%) reported by Friesen et al. (21) . Although°~~~~~~I -. (24) . Although a luteotropic effect of hPL has been reported by Josimovich et al. (25) , the mechanism of this effect is unclear, since hPL does not promote stereoidogenesis in the corpus luteum of either rats (26) or humans (27) . Inhibition of myometrial activity by placental lactogens similar to that reported for prolactin (28) has not been demonstrated. The distribution of oPL binding to rabbit tissues (Table 3 ) closely parallels the distribution of prolactin receptors reported by Posner et al. (17) . (29) . Similarly, the ability of bPL to displace 125I-labeled bGH is only 50% of its ability to displace 125I-labeled bPR in their respective target organs (13) . It is of interest that several hormones (oPL, hPL, and bPR) apparently bind to the same receptor but exert different biological activities. Differences between biological and receptor binding activities have been well documented for other hormones, including glucagon and the catecholamines (30) . This may, in part, reflect the fact that the radioreceptor assay, an in vitro assay, is potentially independent of such variables as activation, transformation, or compartmentalization, which may be important for the expression of hormone activity in vivo. Since the radioreceptor assay measures binding and not biological activity, these differences might be expected to occur if prolactin and placental lactogen hormones have a common binding site but separate active sites. A dissociation between binding and active sites has been established for corticotropin (31) . Although the subprimate placental lactogens appear to bind preferentially to the prolactin receptor, there is also some cross-binding to specific growth hormone receptors (13, 29) . Thus, the biological effects of these hormones may reside in a balance between the activation of the two receptors, much in the same manner as the differential effects of sympathomimetic drugs depend upon their relative potencies at a and , adrenergic receptors (32) .
